Neurocrine Biosciences (NBIX) Receivables - Net (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Receivables - Net for 17 consecutive years, with $887.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 48.9% year-over-year to $887.0 million; the trailing twelve-month figure through Jun 2026 stood at $887.0 million (up 48.9% YoY), and the FY2025 full-year result was $686.8 million, up 43.35% from the prior year.
• Receivables - Net climbed to $887.0 million in Q2 2026 per NBIX's latest filing, from $768.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $887.0 million in Q2 2026 and bottomed at $263.5 million in Q1 2022.
• Historically, Receivables - Net has averaged $493.9 million across 5 years, with a median of $459.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Receivables - Net surged 88.68% in 2022, then increased 9.06% in 2024.
• Over 5 years, Receivables - Net stood at $350.0 million in 2022, then rose by 25.51% to $439.3 million in 2023, then gained by 9.06% to $479.1 million in 2024, then soared by 43.35% to $686.8 million in 2025, then gained by 29.15% to $887.0 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $887.0 million, $768.1 million, and $686.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.